TY - JOUR
T1 - Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals
AU - Lozano-Ojalvo, Daniel
AU - Camara, Carmen
AU - Lopez-Granados, Eduardo
AU - Nozal, Pilar
AU - del Pino-Molina, Lucía
AU - Bravo-Gallego, Luz Yadira
AU - Paz-Artal, Estela
AU - Pion, Marjorie
AU - Correa-Rocha, Rafael
AU - Ortiz, Alberto
AU - Lopez-Hoyos, Marcos
AU - Iribarren, Marta Erro
AU - Portoles, Jose
AU - Rojo-Portoles, Maria Pilar
AU - Ojeda, Gloria
AU - Cervera, Isabel
AU - Gonzalez-Perez, Maria
AU - Bodega-Mayor, Irene
AU - Montes-Casado, Maria
AU - Portoles, Pilar
AU - Perez-Olmeda, Mayte
AU - Oteo, Jesus
AU - Sanchez-Tarjuelo, Rodrigo
AU - Pothula, Venu
AU - Schwarz, Megan
AU - Brahmachary, Manisha
AU - Tan, Anthony Tanoto
AU - Le Bert, Nina
AU - Berin, Cecilia
AU - Bertoletti, Antonio
AU - Guccione, Ernesto
AU - Ochando, Jordi
N1 - Publisher Copyright:
© 2021 The Authors
PY - 2021/8/24
Y1 - 2021/8/24
N2 - The rapid development of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naive individuals. While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naive individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has not been investigated in detail. In this study, we characterize SARS-CoV-2 spike-specific humoral and cellular immunity in naive and previously infected individuals during and after two doses of BNT162b2 vaccination. Our results demonstrate that, while the second dose increases both the humoral and cellular immunity in naive individuals, COVID-19 recovered individuals reach their peak of immunity after the first dose. These results suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2.
AB - The rapid development of mRNA-based vaccines against the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) led to the design of accelerated vaccination schedules that have been extremely effective in naive individuals. While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naive individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has not been investigated in detail. In this study, we characterize SARS-CoV-2 spike-specific humoral and cellular immunity in naive and previously infected individuals during and after two doses of BNT162b2 vaccination. Our results demonstrate that, while the second dose increases both the humoral and cellular immunity in naive individuals, COVID-19 recovered individuals reach their peak of immunity after the first dose. These results suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2.
KW - BNT162b2 vaccine
KW - COVID-19
KW - SARS-CoV-2
KW - T-cell immunity
UR - http://www.scopus.com/inward/record.url?scp=85112532503&partnerID=8YFLogxK
U2 - 10.1016/j.celrep.2021.109570
DO - 10.1016/j.celrep.2021.109570
M3 - Article
C2 - 34390647
AN - SCOPUS:85112532503
SN - 2211-1247
VL - 36
JO - Cell Reports
JF - Cell Reports
IS - 8
M1 - 109570
ER -